Skip to main content

Genome instability in cancer: from mechanisms to the clinic

Guest Editors:
Christopher Lord, PhD, The Institute of Cancer Research, London, UK
Timothy Yap, MD, PhD, MD Anderson Cancer Center, US

Submission Status: Closed   |   Submission Deadline: 30 June 2024

Genome Medicine called for submissions to our Collection focusing on genome instability in cancer. We encouraged submissions of work that expands the mechanistic knowledge of DNA damage, repair, integrity, and stability as well as research that translates these concepts to ultimately target cancer at the bedside.

About the collection

Genome Medicine called for submissions to our Collection focusing on genome instability in cancer.

Tumor initiation, progression, and evolution are often rooted in the malfunctioning of the checkpoints securing genome integrity. Genome instability is a hallmark of cancer, and gives tumor cells many selective advantages, accelerating the evolutionary processes which allow cancers to thrive. 

Maintaining the genomic machinery is not a flawless process: DNA damage, genotoxic stresses, and defects in the repair pathways can all contribute to destabilizing the complex molecular networks keeping the genome intact. Greater understanding of the biology of cancer has led, over the years, to a deeper knowledge of the mechanisms safeguarding genome stability and the many ways in which these can fail. Considering this intrinsic relationship, targeting cancer genomic instability with therapeutics has potential to improve the lives of cancer patients. 

In this Collection, guest edited by Christopher Lord and Timothy Yap, we aim to highlight insights that expand upon our mechanistic knowledge of DNA damage, repair, integrity, and stability as well as research that leverages these concepts to ultimately target cancer at the bedside. We invited the submission of manuscripts with significant clinical and translational impact, dealing with the broader field of genome instability, including:

•  DNA damage and repair;
•  Responses to genotoxic stresses; 
•  Tumor mutation profiling and genome structural rearrangements;
•  Aging, senescence, somatic mutation and their impact on cancer development;
•  Diagnostic tools, risk and prognosis prediction, patient stratification;
•  Response, resistance and sensitization to therapy;
•  Clinical trials and models for therapeutic actionability;
•  Combination approaches, including chemotherapies, radiotherapies and immunotherapies.

We encouraged work that fosters academic-industry partnerships and collaboration among scientists from multi-disciplinary fields.

Image credit: ktsdesign /

Meet the Guest Editors

Back to top

Dr Christopher Lord: The Institute of Cancer Research, London, UK

Chris Lord is Professor of Cancer Genomics at The Institute of Cancer Research, London.  His research focusses on targeted therapies for DNA repair defective cancers, synthetic lethality and drug resistant cancers.

Dr Timothy Yap: MD Anderson Cancer Research Center, US 

Dr Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes.

  1. Somatic copy number alterations are a hallmark of cancer that offer unique opportunities for therapeutic exploitation. Here, we focused on the identification of specific vulnerabilities for tumors harboring ch...

    Authors: Stephan Krieg, Thomas Rohde, Tobias Rausch, Luise Butthof, Lena Wendler-Link, Christoph Eckert, Kai Breuhahn, Bruno Galy, Jan Korbel, Maximilian Billmann, Marco Breinig and Darjus F. Tschaharganeh
    Citation: Genome Medicine 2024 16:83
  2. Natural killer/T cell lymphoma (NKTCL) is a clinically and genetically heterogeneous disease with poor prognosis. Genome sequencing and mutation characterization provides a powerful approach for patient strati...

    Authors: Zegeng Chen, He Huang, Huangming Hong, Huageng Huang, Huawei Weng, Le Yu, Jian Xiao, Zhao Wang, Xiaojie Fang, Yuyi Yao, Jia-Xing Yue and Tongyu Lin
    Citation: Genome Medicine 2024 16:48
  3. Extension of prostate cancer beyond the primary site by local invasion or nodal metastasis is associated with poor prognosis. Despite significant research on tumour evolution in prostate cancer metastasis, the...

    Authors: Srinivasa Rao, Clare Verrill, Lucia Cerundolo, Nasullah Khalid Alham, Zeynep Kaya, Miriam O’Hanlon, Alicia Hayes, Adam Lambert, Martha James, Iain D. C. Tullis, Jane Niederer, Shelagh Lovell, Altan Omer, Francisco Lopez, Tom Leslie, Francesca Buffa…
    Citation: Genome Medicine 2024 16:35
  4. Identifying expressed somatic mutations from single-cell RNA sequencing data de novo is challenging but highly valuable. We propose RESA – Recurrently Expressed SNV Analysis, a computational framework to ident...

    Authors: Tianyun Zhang, Hanying Jia, Tairan Song, Lin Lv, Doga C. Gulhan, Haishuai Wang, Wei Guo, Ruibin Xi, Hongshan Guo and Ning Shen
    Citation: Genome Medicine 2023 15:115

    The Correction to this article has been published in Genome Medicine 2024 16:68

  5. Clonal hematopoiesis (CH) frequently progresses after chemotherapy or radiotherapy. We evaluated the clinical impact of preoperative CH on the survival outcomes of patients with non-small cell lung cancer (NSC...

    Authors: Jae Kwang Yun, Sugyeong Kim, Hongyul An, Geun Dong Lee, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Sehoon Choi and Youngil Koh
    Citation: Genome Medicine 2023 15:111
  6. Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical tr...

    Authors: Anssi Nurminen, Serafiina Jaatinen, Sinja Taavitsainen, Gunilla Högnäs, Tom Lesluyes, Naser Ansari-Pour, Teemu Tolonen, Kerstin Haase, Antti Koskenalho, Matti Kankainen, Juho Jasu, Hanna Rauhala, Jenni Kesäniemi, Tiia Nikupaavola, Paula Kujala, Irina Rinta-Kiikka…
    Citation: Genome Medicine 2023 15:82

Submission Guidelines

Back to top

This Collection welcomes submission of Research, Method, Software, Database, and Guideline manuscripts. Before submitting your manuscript, please ensure you have read our submission guidelines and have formatted your submission correctly.

Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Genome instability in cancer: from mechanisms to the clinic" from the dropdown menu.

You are welcome to enquire about the suitability of your manuscript by emailing our editorial office at

All articles submitted to Collections are peer reviewed in line with the journal’s standard peer review policy and are subject to all of the journal’s standard editorial and publishing policies. This includes the journal’s policy on competing interests. 

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editor or Editorial Board Member who has no competing interests.